Global Bronchodilators Market 2017-2021
Bronchodilators are a type of medication, which make breathing easy by relaxing the muscles in the lungs and widening the airways (bronchi). They are used to treat the breathing problems, majorly asthma and COPD. Short-acting bronchodilators are the first-line therapy, which is widely used in bronchodilators. These agents have a short-term (2-4 hours) duration of action and therefore require multiple dosages. Whereas, long-acting bronchodilators, which are introduced recently, have an extended period of action. They reduce the process of multiple dosages. Therefore, they are more effective than the short-term bronchodilators. Technavio’s analysts forecast the global bronchodilators market to grow at a CAGR of 4.78% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bronchodilators market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bronchodilators Market 2017-2021
Technavio recognizes the following companies as the key players in the global bronchodilators market: AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, and GlaxoSmithKline.
Other Prominent Vendors in the market are: ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Innovative technologies for drug delivery. Technological advances and innovations in the healthcare industry have resulted in the development of drugs and delivery devices as per the end-user requirement. New technologies in the development of drugs, which can be easily administered and exhibit higher efficacy are more preferred in the market. For instance, in April 2016 AstraZeneca received approval from the US FDA for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol for patients suffering from COPD. The drug is the company's first product to use its patented Co-Suspension Technology.”
According to the report, one of the major drivers for this market is Market potential toward mAb. Monoclonal antibodies are expected to boost the market growth for the treatment of asthma, owing to the development of target specific drugs. mAb blocking immunoglobulin E (IgE) are specifically approved for the treatment of allergic asthma. Also, the mAb against immunoglobulin or specific cytokines, which are known to be important in the initiation or persistence of asthmatic inflammation are being developed.
Further, the report states that one of the major factors hindering the growth of this market is Increased preference for CAM. People who have asthma tend to adopt alternative methods of treatment instead of pharmacologic treatments. According to a recent report, in the US, more than 15% of the population suffer from allergic diseases including allergic asthma, allergic rhinitis, and atopic dermatitis, and more than 40% of people used CAM for these conditions. The usage of CAM for allergic conditions is higher in some European countries, because of efficacy, safety, and low cost of some therapies. The lack of a well-designed clinical trial for these treatments makes it difficult to determine the safety and effectiveness over pharmacotherapies.
AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.